Stay updated on Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial

Sign up to get notified when there's something new on the Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    Study status updated to Completed with 137 participants enrolled and a completion date of 2026-01-28, with the record revision to v3.4.2. The previous funding notice and the 'Active, not recruiting' indicator were removed.
    Difference
    0.7%
    Check dated 2026-02-11T09:27:03.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Added a site-wide notice about a lapse in government funding, stating the NIH Clinical Center is open and directing users to cc.nih.gov and opm.gov for status updates. Updated the system revision from v3.4.0 to v3.4.1.
    Difference
    0.3%
    Check dated 2026-02-04T05:39:08.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The page now includes a glossary toggle and updated QC-related labels and revision information (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0), replacing the previous labels and version (Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4).
    Difference
    0.2%
    Check dated 2026-01-28T03:55:19.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    Added EU CT registry identifier 2023-503587-17-00 and updated key dates to 2026-01-28, while removing the previous registry identifier 2023-503587-17 and earlier dates.
    Difference
    0.3%
    Check dated 2026-01-21T02:17:39.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    The page now displays revision v3.3.4, replacing the previous revision v3.3.3.
    Difference
    0.0%
    Check dated 2026-01-14T01:42:44.000Z thumbnail image
  7. Check
    63 days ago
    Change Detected
    Summary
    Locations section updated to add new study sites across the United States, Australia, Canada, and several European regions, and older location entries were removed. The revision also includes a new version tag (v3.3.3).
    Difference
    1%
    Check dated 2025-12-23T13:31:46.000Z thumbnail image

Stay in the know with updates to Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial page.